CHIR-98014

CHIR-98014 is a potent, cell-permeable GSK-3 inhibitor with IC50s of 0.65 and 0.58 nM for GSK-3α and GSK-3β, respectively; it shows less potent activities against cdc2 and erk2.

Product Specifications

CAS Number

[252935-94-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

GSK-3

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/CHIR-98014.html

Purity

98.44

Solubility

DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

ClC1=CC(Cl)=CC=C1C2=NC(NCCNC3=CC=C([N+]([O-])=O)C(N)=N3)=NC=C2N4C=CN=C4

Molecular Formula

C20H17Cl2N9O2

Molecular Weight

486.31

Precautions

H302, H315, H319, H335

References & Citations

[1]Ring DB, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52 (3) :588-95.|[2]Naujok O, et al. Cytotoxicity and activation of the Wnt/beta-catenin pathway in mouse embryonic stem cells treated with four GSK3 inhibitors. BMC Res Notes. 2014 Apr 29;7:273.|[3]Zajkowski T, et al. Stabilization of microtubular cytoskeleton protects neurons from toxicity of N-terminal fragment of cytosolic prion protein. Biochim Biophys Acta. 2015 Oct;1853 (10 Pt A) :2228-39.